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Impact of early cytomegalovirus infection and disease on long-
term recipient and kidney graft survival.
Background. The impact of cytomegalovirus (CMV) infec-
tion and disease on long-term outcome after kidney transplan-
tation is still unsettled.
Methods. Between 1994 and 1997, 397 consecutive first kid-
ney graft recipients and 74 retransplants were included in the
study and followed prospectively until December 31, 2001.
CMV infection (CMV pp65 antigenemia) and CMV disease
were recorded once weekly during the first 100 days after trans-
plantation. No CMV prophylaxis or preemptive therapy was
given. In a multiple Cox proportional hazard model allowing
time-dependent covariates, the effects of asymptomatic CMV
infection and CMV disease, recipient age and gender, retrans-
plantation, living donor, panel-reactive cytotoxid antibodies,
acute rejection, and graft loss were tested on overall mortality
beyond 100 days post-transplantation. In a similar analysis, the
effect of asymptomatic CMV infection and CMV disease plus
other factors were tested on death censored graft loss beyond
100 days.
Results. Median (range) follow up time was 66.6 (<1–86.9)
months. The incidence of CMV infection and disease during
the first 100 days was 62.8% and 23.4%, respectively. The num-
ber of total deaths was 96 (20%), 82 occurred after the first
100 days. Independent risk factors for overall mortality beyond
100 days were asymptomatic CMV infection, RR = 2.90 (95%
CI 1.61–5.22) (P = 0.001), CMV disease, RR = 2.50 (95% CI
1.31–4.79) (P = 0.006), both compared to no infection or dis-
ease, recipient age, RR = 1.066 per year (95% CI 1.048–1.084)
(P < 0.001), and graft loss in the whole study period RR = 7.88
(95% CI 4.75–13.08) (P < 0.001). Asymptomatic CMV infection
and CMV disease were not independent risk factors for death
censored graft loss, but they significantly reduced graft survival
uncensored for death, (log rank P = 0.001, respectively).
Conclusion. Asymptomatic CMV infection and overt CMV
disease during the first 100 days increase the risk of recipient
mortality beyond 100 days. This raises the question whether
CMV prophylaxis should be given routinely after kidney
transplantation.
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Cytomegalovirus (CMV) is the single most important
infectious agent in kidney allograft recipients and is a
major source of morbidity [1].
Previously we have investigated the natural history of
CMV infection and disease in kidney allograft recipi-
ents during the first 100 days post-transplantation [2].
We found that CMV infection and disease are indepen-
dent risk factors for clinical acute rejection during the first
100 days post-transplantation [3].
Most CMV infection and disease occur during the first
100 days after kidney transplantation. The impact of this
early CMV infection and disease on long-term outcome
after transplantation remains controversial. Some clinical
studies indicate an association of CMV disease with an
increased risk of kidney graft loss [4–6]. However, oth-
ers fail to show such an association [7, 8]. The present
study was designed to follow kidney allograft recipients
prospectively and evaluate the influence of early CMV
infection and disease on long-term recipient and graft
survival. First, the objectives were to study recipient over-
all mortality and death-censored graft loss (deaths with
functioning grafts are excluded) beyond 100 days post-
transplantation. We also wanted to evaluate uncensored
graft loss (death with functioning graft is considered
as graft failure) and hospital-treated infectious dis-
eases other than CMV disease beyond 100 days post-
transplantation. Our hypothesis was that CMV infection
and disease during the first 100 days might have a detri-
mental effect on overall recipient mortality and death-
censored graft loss beyond 100 days post-transplantation.
No patients in this study received CMV prophylaxis
or preemptive therapy. Only deferred anti-CMV therapy
was given, implying that positive antigenemias were only
treated when the patients presented symptoms related to
CMV disease.
METHODS
Patients and study design
A cohort of 496 adult recipients received a kidney
transplant at our center in the period from October
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Table 1. Recipient and donor characteristics
First transplants Retransplants
N = 397 N = 74 P value
Recipient age years mean (range) 50 (17–80) 42 (18–67) <0.01
Gender female/male 126/271 29/45 NS
Living/cadaveric 157/240 15/59 0.002
Donor age years mean (range) 45 (0–81) 42 (5–81) NS
Cold ischemia hours mean (range) 9.1 (0–31) 13.1 (<1–28.6) <0.01
Preemptive transplantation number (%) 100 (25)
Panel-reactive cytotoxic antibodies positivity number (%) 15 (4) 19 (26) <0.01
HLA-AB mismatches mean ± SD 2.1 ± 1.1 1.8 ± 1.1 0.04
HLA-DR mismatches number (%) NS
0 150 (38) 38 (51)
1 226 (57) 31 (42)
2 21 (5) 5 (7)
HLA is human leukocyte antigen. Chi-squared tests were used to compare categorical data and unpaired t tests were used to compare normally distributed data
between first transplants and retransplants.
1994 to July 1997, 417 first transplantations and 86 re-
transplantations. The cohort has been described in detail
[2]. Multiorgan transplantations were excluded. Ex-
cluded from analyses were also four CMV IgG-negative
patients receiving transplants from CMV seronegative
donors (D− R−) who developed CMV pp65 antigene-
mia without symptoms of CMV infection, probably due
to accidental sample labeling or handling. Six patients
received more than one kidney graft during the study pe-
riod, and only the first transplantation is considered in
the statistical analyses.
Adequate data for prospective investigation of
CMV infection and disease the first 100 days post-
transplantation were obtained for 471 of the patients. The
present manuscript deals with a prospective follow up
of these 471 patients until December 31, 2001. Of these,
397 were first transplantations and 74 were retransplan-
tations. Donor and recipient demographic characteristics
are shown in Table 1.
Information of death-censored graft losses, total
deaths, and cardiovascular events and cardiovascular
deaths were recorded for all patients over the study pe-
riod. All infectious diseases requiring hospitalization (ex-
cept from CMV infections) occurring after the first 100
days post-transplantation were recorded. Data were col-
lected from the Norwegian Renal Registry, and deaths
were double-checked with the national census.
Graft losses were censored for death (death with func-
tioning graft is not considered as graft loss). The date
of graft loss was defined as the day the patient started
dialysis for more than 30 days or was retransplanted.
The study was approved by the Datainspectorate, Oslo,
Norway, and by the Regional Ethics Committee.
Antimicrobial prophylaxis
Primary prophylaxis against Pneumocystis carinii
pneumonia with trimethoprim-sulfamethoxazole (or
trimethoprim alone when allergy to sulfa was suspected)
was given to all the patients for 6 months. Prophylaxis
against CMV or other herpes viruses was not given.
Immunosuppressive treatment
Cyclosporin (CsA), steroids, and azathioprine con-
stituted the standard immunosuppressive therapy. All
patients received prednisolone and all except two (both
retransplant patients) were initially treated with CsA. Pa-
tients with stable renal function 1 year after transplanta-
tion had the oral prednisolone dose reduced from 10 mg
to 7.5 mg or 5 mg once daily.
Among first renal transplants, 362 (91%) received
azathioprine versus 60 (81%) in retransplant patients.
Mycophenolate mofetil (MMF) was usually given as a
substitute to those who did not receive azathioprine. In
some cases of rejection or side effects from the stan-
dard medication a small percentage of the patients were
switched to MMF or tacrolimus during the study. Details
of the immunosuppressive regimen have been presented
previously [2].
Rejection
Acute rejection episodes were recorded during the first
100 days after transplantation and were treated with bo-
luses of methylprednisolone (clinical rejection episodes).
Rejection episodes were considered steroid resistant if
no significant decrease in serum creatinine was observed
on the fifth day after start of standard methylprednisolone
treatment. In such cases antithymocyte globulin or OKT3
was given. Biopsies were taken in most cases and in all
steroid-resistant episodes.
CMV serology
IgG antibodies to CMV were detected by the Ab-
bott Axsym system (Abbott, Chicago, IL, USA). Serum
samples for CMV serology were taken immediately
prior to transplantation and thereafter together with all
specimens for CMV pp65 assay and repeatedly tested for
CMV IgG until two consecutive samples tested positive.
CMV pp65 assay
CMV pp65 lower matrix protein was detected in leuko-
cytes from ethylenediaminetetraacetic acid (EDTA)
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blood samples. The method was a previously described
modification of a reported procedure [9]. CMV infection
was defined as a result of one or more cells positive for
CMV pp65 antigen per 105 leukocytes.
In the first part of the study period screening was per-
formed every second week during the first 100 days after
transplantation until suspicion of CMV disease or the
CMV pp65 antigen test became positive. Thereafter, the
test was performed once or twice a week. Also, with signs
of rejection or other adverse events, the test was per-
formed more frequently. In the second half of the study
period, screening was performed at least once a week in
all patients during the first 100 days post-transplantation.
The results of the routine antigenemia testing were
not blinded, and the treating physicians were informed
about the results. Retrospective examination of all the pa-
tient case records revealed that eight CMV pp65 antigen
positive patients received ganciclovir intravenously with-
out fulfilling the definition of CMV disease. These eight
patients had actually received preemptive treatment and
were excluded from the study.
CMV disease
CMV disease was registered during the first 100 days
after transplantation while the patients still were under
surveillance at the National Hospital, and the incidence is
previously described in detail [2]. The definition of CMV
disease was by detection of CMV in a clinical specimen
accompanied either by CMV syndrome with fever, mus-
cle pain, leucopenia, and/or thrombocytopenia (other
causes excluded), or by organ involvement such as hep-
atitis, gastrointestinal ulceration, pneumonitis, or retini-
tis. Leukopenia was defined as a leukocyte count less than
4 × 109/L and thrombocytopenia when the cell count was
less than 100 × 109/L in peripheral blood. Hepatitis was
defined as a rise in liver enzymes of at least twice the ini-
tial values without other known cause. Gastrointestinal
CMV ulceration was confirmed by endoscopy and biopsy.
Presence of CMV in tissue biopsies was detected by im-
munohistochemistry or growth of virus in cell cultures.
CMV disease was treated with intravenous ganciclovir,
and none of these patients had their immunosuppressive
treatment reduced.
Clinical monitoring
After leaving the hospital the patients were seen on an
outpatient basis and stayed in a neighborhood residence
during the first 100 days post-transplantation. Thereafter,
they were under surveillance by their local nephrologist
who yearly reported data concerning serum creatinine,
dialysis status, medications, infections treated in hospital,
blood pressure, adverse events, and deaths to the Norwe-
gian Renal Registry.
Statistics
Chi-squared tests were used to compare categorical
data and unpaired t tests were used to compare nor-
mally distributed data between first transplants and re-
transplants. The Cox proportional hazard model was used
to estimate the effect of CMV infection, CMV disease,
and other covariates on death-censored graft loss, over-
all mortality, cardiovascular events/deaths, and infection
episodes (except from CMV infections) demanding hos-
pitalization beyond 100 days post-transplantation, re-
spectively. For estimating the effect of graft loss in the
whole study period on overall mortality and cardiovascu-
lar mortality beyond 100 days post-transplantation a Cox
proportional hazard model which allows time dependent
covariates was used.
The effects of asymptomatic CMV infection, CMV dis-
ease, and other factors on the serum creatinine values at
the end of follow-up were assessed by univariate and mul-
tiple linear regression analysis.
To test the effect of asymptomatic CMV infection and
of CMV disease during the first 100 days on graft survival
not censored for death beyond 100 days (death with func-
tioning graft considered as graft loss) Kaplan-Meier anal-
ysis was used, and statistical significance was estimated
using the log-rank test.
The statistical software SPSS (SPSS 11, Inc., Chicago,
IL, USA) was used to perform the calculations.
RESULTS
General outcome
The median (range) observation time for all patients
was 66.6 (<1 to 86.9) months.
Altogether 96 patients (20.4%) died during follow-
up, 82 of the deaths occurred beyond 100 days post-
transplantation (Table 2). In the 96 patients who died,
median (range) time from transplantation to death was
38.6 (<1 to 79.4) months. Only one death was directly
caused by CMV disease in a D+ R+ recipient who de-
veloped bleeding CMV duodenal ulcer and subsequently
multiple organ failure.
In the whole study period there were 35 cardiovascu-
lar deaths with the following causes: myocardial ischemia
and infarction (N = 12), cardiac failure (N = 7), cardiac
arrest/sudden death (N = 9), fluid overload/pulmonary
edema (N = 1), and cerebrovascular events (N = 6) (ex-
cept ruptured vascular aneurysm). Twenty-nine of these
deaths occurred after 100 days post-transplantation. Me-
dian (range) time to cardiovascular deaths was 38.4
(<1 to 79.4) months.
The total number of death censored kidney graft loss
was 58 (12%) (Table 2). Median (range) time from trans-
plantation to death censored kidney graft loss was 21.2
(<1 to 81.2) months. Forty-nine (84%) of all graft losses
were caused by rejection, in three (5%) cases the graft
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Table 2. Mortality, graft losses, and inhospital-treated infections in
471 patients
First
transplants Retransplants
N = 397 N = 74
Death from all causes number (%) 84 (21) 12 (16) NSa
Cardiovascular deaths number (%) 32 (8) 3 (4) NSa
Deaths other than cardiovascular 52 (13) 9 (12) NSa
number (%)
Malignant disease 12 (3) 1 (1)
Infectious disease 18 (5) 5 (7)
Other causes 22 (6) 3 (4)
Death-censored kidney graft loss 45 (11) 13 (18) NSa
number (%)
Hospital-treated infectious 120 (30) 28 (38) NSa
diseases [other than
cytomegalovirus (CMV)] after
100 days post-transplantation
aVersus first transplants, chi-squared test.
never functioned, in one (2%) case urologic complica-
tions caused the graft loss, and finally five (9%) recipients
experienced recurrence of the original kidney disease.
Eighteen (31%) of these lost the graft function during
the first 100 days after transplantation.
Sixteen of the 58 patients with death censored kidney
graft loss were retransplanted during the study period,
12 originally in the first transplant group and four in
the retransplant group. The number of hospital-treated
infectious disease (except from CMV disease) beyond
100 days post-transplantation was 158 (34%).
CMV infection and disease
The overall incidence of CMV infection in all patients
during the first 100 days after transplantation was 63%.
The relative incidence of primary infection (D+ R−)
and CMV reactivation (D± R+) was the same, 69% and
67%, respectively. However, the rate of CMV disease was
nearly three times higher in the primary infected group
(54% vs. 19%, P < 0.0001) [2].
Allograft rejection episodes
Clinical rejection episodes were diagnosed in 59% of
the patients and were biopsy verified in 61% of the cases.
Risk factors for overall mortality beyond 100 days
posttransplantation
In a Cox regression analysis of all kidney graft recip-
ients surviving the first 100 days (N = 457), potential
predictors were tested as independent risk factors for
overall mortality beyond 100 days post-transplantation.
These factors and univariate analyses of overall mortality
beyond 100 days postoperatively are shown in Table 3.
Independent risk factors for overall mortality beyond
100 days tested in a multiple Cox proportional hazard
model are shown in Figure 1: asymptomatic CMV infec-
tion (RR = 2.90), CMV disease (RR = 2.50) (both these
Table 3. Univariate analyses of overall mortality beyond 100 days
post-transplantationa
Variable Risk ratio 95% CI P value
Asymptomatic CMV infectionb 2.81 1.58–4.98 <0.001
CMV diseaseb 2.38 1.25–4.54 0.008
CMV pp65 positive cells ×
days (AUC)c
1–50 2.74 1.30–5.80 0.008
51–900 1.93 0.98–3.83 0.06
901–5000 3.38 1.74–6.57 <0.001
>5000 3.12 1.59–6.12 0.001
Panel-reactive cytotoxic 1.16 0.50–2.66 0.7
antibodies
Patient age 1.066 1.048–1.084 <0.001
Patient gender 1.01 0.64–1.61 1.0
Retransplantation 0.81 0.43–1.52 0.5
Living donor 0.45 0.26–0.75 0.003
Acute clinical rejection 1.91 1.18–3.08 <0.01
first 100 days
Death-censored graft loss 2.94 1.28–6.75 0.01
first 100 days
Death censored graft loss 6.32 3.89–10.29 <0.001
in total study periodd
Abbreviations are: CMV, cytomegalovirus; AUC, area under the curve.
aThe statistical test used is a Cox proportional hazard model, which for the
variable death-censored graft loss in total study period allows time-dependent
covariates.
bRecipients with no CMV infection or disease is the reference CMV group.
cAUC for CMV pp65 levels measured during the first 100 days after transplan-
tation.
dTested as a time-dependent covariate.
factors are compared to no CMV infection or disease),
patient age (RR = 1.066 per year) (95% CI 1.048 to 1.084,
P < 0.001) and death censored graft loss in total study pe-
riod (RR = 7.88).
In a similar multiple Cox regression analysis the same
potential predictors as above were tested as independent
risk factors for overall mortality beyond 100 days, with
the exception that death-censored graft loss in the whole
study period was replaced by death-censored graft loss
during only the first 100 days. The results were essentially
the same with respect to CMV infection, CMV disease,
and patient age. Death-censored graft loss during the first
100 days did not significantly increase the risk of overall
mortality (RR = 2.17) (95% CI 0.90 to 5.22, P = 0.08)
(see Fig. 1).
CMV infection as a risk factor for overall mortality
beyond 100 days was also assessed by evaluating the
area under the curve (AUC) for CMV pp65 levels mea-
sured during the first 100 days, expressed as CMV pp65-
positive cells × days. The AUC was estimated according
to the trapezoidal method [10]. AUC was divided into
categories with equal number of patients in the groups
with CMV pp65 AUC of more than zero: 1 to 50, 51 to
900, 901 to 5000, and >5000. The univariate Cox regres-
sion analysis is shown in Table 3. Multiple Cox regression
analysis revealed that the same factors as above were in-
dependent predictors for overall mortality beyond 100
days (Fig. 2).
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1 2 3 4 5 6 7 8 9 10 11 12
Relative risk for overall mortality
CMV infection, P < 0.001
Patient age, P < 0.001
Death censored graft loss in
whole study period, P < 0.001
Death censored graft loss 
first 100 days after Tx,
P = 0.08
CMV disease, P = 0.006
Fig. 1. Independent risk factors for
overall mortality beyond 100 days post-
transplantation. Relative risks (RR) and
95% CI are indicated. For patient age (RR =
1.066 per year) (95% CI 1.048–1.084). Death-
censored graft loss in the whole study period
and during the first 100 days were tested
in two separate multiple Cox proportional
hazard models, allowing time-dependent
covariates in the analysis with death-censored
graft loss in the whole study period. The risk
ratios, confidence intervals, and P values
for the covariates cytomegalovirus (CMV)
infection, CMV disease, and patient age are
given from the analysis with death-censored
graft loss in the whole study period. The
corresponding data with death-censored graft
loss during the first 100 days as a covariate
are essentially the same.
1 2 3 4 5 6 7 8 9 10 11 12
Relative risk for overall mortality
CMV pp65 AUC,
Patient age, P < 0.001
Death censored graft loss in
whole study period, P < 0.001
1-50, P = 0.008
51-900, P = 0.04
901-5000, P = 0.001
>5000, P < 0.001
Fig. 2. Indepedent risk factors for over-
all mortality beyond 100 days post-
transplantation. Relative risks (RR) and
95% CI are indicated. For patient age (RR
= 1.066 per year) (95% CI 1.048–1.084). The
statistical test used is multiple Cox propor-
tional hazard model allowing time-dependent
covariates.
Risk factors for cardiovascular mortality beyond 100 days
post-transplantation
Separate univariate and multiple Cox regression anal-
yses were performed for cardiovascular mortality beyond
100 days post-transplantation. Univariate analyses are
shown in Table 4. Independent risk factors for cardio-
vascular mortality after 100 days in multiple analyses
were patient age and death-censored graft loss in the
whole study period, while CMV disease and acute clinical
rejection the first 100 days were risk factors of borderline
significance (see Fig. 3).
In a separate multiple Cox regression analysis of non
cardiovascular mortality beyond 100 days (N = 54), recip-
ient age, and death-censored graft loss still remained in-
dependent predictors in addition to asymptomatic CMV
infection (compared to no infection or disease). For
asymptomatic CMV infection (RR = 3.67) (95% CI 1.73–
7.78, P = 0.001), CMV disease did not reach statistical
significance (RR = 2.11) (95% CI 0.87–5.11, P = 0.1).
Risk factors for death-censored kidney graft loss
beyond 100 days post-transplantation
A number of potential predictors were tested as inde-
pendent risk factors for death-censored graft loss beyond
Table 4. Univariate analyses of cardiovascular mortality beyond 100
days post-transplantationa
Variable Risk ratio 95% CI P value
Asymptomatic CMV infectionb 1.64 0.63–4.23 0.3
CMV diseaseb 2.73 1.06–7.04 0.04
Panel-reactive cytotoxic antibodies 0.53 0.07–3.91 0.5
Recipient age 1.080 1.048–1.112 <0.001
Retransplantation 0.60 0.18–1.97 0.4
Living donor 0.4 0.17–1.01 0.05
Female gender 0.66 0.28–1.53 0.3
Acute clinical rejection first 100 days 4.65 1.62–13.35 0.004
Death-censored kidney graft 8.42 3.88–18.26 <0.001
loss in the whole study period
CMV is cytomegalovirus.
aThe statistical test used is a Cox proportional hazard model, for the vari-
able death censored graft loss a Cox proportional hazard model allowing time-
dependent cofactors is used.
bRecipients with no CMV infection or disease is the reference CMV group.
100 days post-transplantation. The factors were asymp-
tomatic CMV infection and CMV disease (both com-
pared to no CMV infection or disease), clinical rejection
during the first 100 days, human leukocyte antigen re-
gion D, sublocus R (HLA-DR) zero vs. one and two mis-
matches, HLA-AB mismatches, panel-reactive cytotoxic
antibodies, donor age, retransplantation, living donor,
female gender, serum creatinine, and antihypertensive
medication at 100 days after transplantation. These
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Relative risk for cardiovascular mortality
Patient age, P < 0.001
Acute clinical rejection,
P = 0.06
Death censored graft loss
in whole study period,
P < 0.001
CMV disease, P = 0.06
Fig. 3. Relative risk (RR) and 95% CI for
cardiovascular mortality after 100 days post-
transplantation. For patient age (RR = 1.085
per year) (95% CI 1.052–1.118). The statisti-
cal test used is a multiple Cox hazard model
allowing time-dependent covariates.
factors were tested in a univariate Cox proportional haz-
ard model (Table 5).
The same factors were tested in a multiple Cox pro-
portional hazard model. Independent risk factors for
death-censored kidney graft loss beyond 100 days post-
transplantation were HLA-AB mismatches (RR = 1.49)
(95% CI 1.09–2.04, P = 0.01), donor age (RR = 1.028 per
year) (95% CI 1.003–1.053, P = 0.03), and serum creati-
nine at 100 days after transplantation (RR = 1.006) (95%
CI 1.000–1.011, P = 0.007). Clinical rejection episodes
were of borderline statistical significance (RR = 2.29)
(95% CI 0.98–5.38, P = 0.06).
This analysis was repeated with HLA-DR plus AB
mismatches (0 to 6) as one continuous variable replac-
ing HLA-DR and HLA-AB mismatches as two separate
variables. The results were essentially the same, for HLA-
DR plus AB mismatches (RR = 1.43) (95% CI 1.11–1.83,
P = 0.006) (data not shown).
CMV pp65 AUC was not found to be an independent
risk factor for death-censored graft loss beyond 100 days
(data not shown).
Risk factors for impaired long-term graft function
Analyses of the effects of asymptomatic CMV infec-
tion, CMV disease, and other factors on long-term graft
function were also performed. Serum creatinine was reg-
istered at the turn of each year and the last value was
used for analysis of long-term graft function. In patients
who died during follow-up the last available serum crea-
tinine was used. In cases with censored graft loss, the last
available serum creatinine before graft loss is used in the
analyses. Univariate analyses of serum creatinine at the
end of follow-up are shown in Table 6, and the multiple
analysis is shown in Table 7. The statistical tests used are
linear regression. The results were essentially the same as
for uncensored graft loss. Asymptomatic CMV infection
and CMV disease were not independent risk factors for
serum creatinine at the end of follow-up or for uncen-
sored graft loss.
Table 5. Univariate analyses of death-censored kidney graft loss
beyond 100 days post-transplantationa
Variable Risk ratio 95% CI P value
Asymptomatic CMV infectionb 1.24 0.58–2.65 0.6
CMV diseaseb 1.99 0.91–4.37 0.09
Clinical rejection episodes 3.81 1.69–8.62 0.001
first 100 days
HLA-DR one mismatchc 1.56 0.79–3.11 0.2
HLA-DR two mismatchesc 1.88 0.53–6.66 0.3
HLA-AB mismatches 1.43 1.07–1.92 0.02
Panel-reactive cytotoxic antibodies 1.90 0.67–5.34 0.2
Donor age 1.046 1.023–1.070 <0.001
Retransplantation 1.63 0.77–3.42 0.2
Living donor 0.85 0.44–1.63 0.6
Female gender 0.98 0.51–1.91 1.0
Serum creatinine at 100 days 1.009 1.005–1.013 <0.001
after transplantation
Medication for hypertension at 0.94 0.48–1.82 0.9
100 days after transplantation
Abbreviations are: HLA, human leukocyte antigen; CMV, cytomegalovirus.
aThe statistical test used is a Cox proportional hazard model.
bRecipients with no CMV infection or disease is the reference CMV group.
cHLA zero mismatches is the reference group.
Graft survival uncensored for death
With death considered as a graft loss, overall graft
survival from transplantation through the whole study
period was 73%. In patients with functioning graft at
100 days post-transplantation, asymptomatic CMV infec-
tion during the first 100 days was associated with 74%
graft survival compared with 86% graft survival in pa-
tients with no CMV infection or disease (log-rank P =
0.001) (patients with CMV disease, death, or graft loss
during the first 100 days were excluded from analysis).
Similarly, CMV disease during the first 100 days was
associated with 71% graft survival compared to 86% graft
survival in those with no CMV infection or disease (pa-
tients with asymptomatic CMV infection, death, or graft
loss were excluded from analysis, log-rank P = 0.001).
Kaplan-Meier survival curves for those with CMV infec-
tion and those with CMV disease are shown in Figure 4A
and B, respectively.
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Table 6. Univariate analyses of serum creatinine at the end of follow upa
Variable Estimates 95% CI for estimates SE P value
Asymptomatic CMV infectionb 8.87 −13.50–31.27 11.39 0.4
CMV diseaseb 49.40 23.25–75.56 13.31 <0.001
Acute clinical rejection first 100 days 55.57 36.12–75.03 9.90 <0.001
HLA DR 0 vs. one and two mismatches 25.26 5.08–45.43 10.26 0.01
HLA AB mismatches 4.48 −4.65–13.60 4.64 0.3
Panel-reactive cytotoxic antibodies −13.55 −54.42–27.31 20.79 0.5
Donor age 2.46 1.90–3.03 0.29 <0.001
Retransplantation 20.10 −7.11–47.31 13.84 0.1
Living donor −10.76 −31.34–9.82 10.47 0.3
Female gender −22.60 −43.77–−1.42 10.77 0.04
Serum creatinine at 100 days after transplantation 1.01 0.85–1.18 0.09 <0.001
Medication for hypertension at 100 days after transplantation 1.88 −19.52–23.27 10.89 0.9
Abbreviations are: CMV, cytomegalovirus; HLA, human leukocyte antigen.
aThe statistical test used is linear regression.
bThe effect of asymptomatic CMV infection and CMV disease on serum creatinine are performed in the same analysis.
Risk factors for hospital-treated infections other
than CMV beyond 100 days post-transplantation
In univariate and multiple Cox proportional hazard
models a number of variables were tested as inde-
pendent risk factors for hospital-treated infectious dis-
ease (with the exception from CMV infections) beyond
100 days post-transplantation. The variables were CMV
infection (CMV disease excluded) and CMV disease dur-
ing the first 100 days after transplantation, acute clinical
rejection episodes during the first 100 days after trans-
plantation, HLA-DR one and two mismatches, HLA-AB
mismatches, panel-reactive cytotoxic antibodies, donor
age, recipient age, retransplantation, living donor, female
gender of recipient, serum creatinine, and hypertension
medication at 100 days after transplantation. None of
these variables came out as independent risk factors for
hospital-treated infections.
DISCUSSION
In this prospective study of 471 consecutive renal trans-
plant recipients, both asymptomatic CMV infection and
CMV disease compared to no CMV infection during the
first 100 days after transplantation were independent risk
factors for overall mortality beyond 100 days. To our
knowledge the present study is the first to show that early
asymptomatic CMV infection is an independent risk fac-
tor for recipient death. Our data are in accordance with
two previous reports of a detrimental effect of CMV dis-
ease on renal transplant recipient survival [8, 11]. These
studies comprised fewer patients and the immunosup-
pressive protocol (including antilymphocyte globulin in-
duction) differed from the present study. Moreover, in
one of these studies the CMV diagnosis was based on
serology and urinary culture, which are less sensitive and
less specific tests than those available today [11]. CMV
viremia is also found to be associated with death in pedi-
atric lung transplant recipients [12]. Moreover, after liver
transplantation CMV disease is found to be a significant
risk factor for patient death [13].
Table 7. Independent risk factors of serum creatinine at the end of
follow-upa
95% CI
Variable Estimates for estimates SE P value
Acute clinical rejection 12.86 −5.48–31.20 9.33 0.2
first 100 days
HLA DR zero vs. one 17.78 0.32–35.25 8.89 0.05
and two mismatches
Donor age 1.42 0.88–1.96 0.28 <0.001
Serum creatinine at 100 days 0.78 0.60–0.97 0.09 <0.001
after transplantation
HLA is human leukocyte antigen.
aThe statistical test used is multiple linear regression. Acute clinical rejection
did not reach statistical significance.
The AUC for CMV pp65 is a way to evaluate the
“overall” viral load considering both duration and load
of antigenemia in one parameter. The AUC concept has
suggested advantages over quantification of viral load in
predicting the clinical role for CMV antigenemia [10].
However, there were essentially no differences between
the quartiles of CMV pp65 AUC as risk factors for recip-
ient death beyond 100 days post-transplantation in the
present study.
A possible causal association has been suggested be-
tween CMV and atherosclerosis. Such a mechanism could
be a plausible explanation of increased mortality in the
CMV infection and disease groups. Several authors have
reported an association between CMV antibodies and
coronary restenosis after atherectomy, but others have
not found any association [14–17]. However, there is lit-
tle epidemiologic proof of any links between CMV infec-
tion and classic native atherosclerois [18–20]. Indeed, in
univariate analysis CMV disease was found to be an in-
dependent predictor of cardiovascular mortality beyond
100 days post-transplantation while asymptomatic CMV
infection did not reach statistical significance. Although
CMV disease was a risk factor of only borderline signifi-
cance in multiple analysis this study was not powered to
show an effect of CMV disease or asymptomatic CMV
infection on cardiovascular death. On the other hand,
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Fig. 4. Kaplan-Meier analysis of graft survival not censored for death
beyond 100 days post-transplantation. (A) According to asymptomatic
cytomegalovirus (CMV) infection during the first 100 days (N = 182)
or no CMV infection (N = 159). Patients with CMV disease dur-
ing the first 100 days post-transplantation are excluded from analy-
sis (N = 110). Excluded are also patients with graft loss or death
during the first 100 days (N = 29). Nine of these patients also
suffered from CMV disease. The difference is significant (log-rank
P = 0.001). (B) According to CMV disease occurring during the first
100 days (N = 101) or no CMV disease or infection (N = 159). Patients
with asymptomatic CMV infection during the first 100 days are excluded
from analysis (N = 186). Four of these patients also suffered from graft
loss or death during the first 100 days. Excluded are also patients with
graft loss or death during the first 100 days (N = 29). The difference is
significant (log-rank P = 0.001).
multiple analyses revealed that asymptomatic CMV
infection was an independent predictor of non-
cardiovascular mortality. This indicates that also factors
other than atherosclerosis might be involved with the in-
creased mortality caused by CMV in this study.
Ganciclovir-treated CMV disease is reported to be an
independent predictor of post-transplant diabetes mel-
litus in renal transplant recipients [21]. This raises the
question whether occurrence of diabetes mellitus con-
tributes to the increased mortality. Unfortunately, oral
glucose tolerance test for surveillance of post-transplant
diabetes mellitus was not introduced as a routine in our
center at that time and such a hypothesis remains specu-
lative. Nevertheless, the important finding of the present
study is the excess of overall mortality associated with
CMV infection and disease.
The present study revealed no detrimental effect of
early CMV infection or disease on death-censored graft
loss. There are only a few other studies investigating CMV
disease as risk factor for death-censored graft loss. One
example is a study of Humar et al [5], showing that CMV
disease is a significant risk factor for death-censored graft
loss, but only in the presence of acute rejection. How-
ever, when analyzing graft survival not censored for death
(death with functioning graft considered as graft failure)
in the present study, both asymptomatic CMV infection
and CMV disease significantly reduced the risk of graft
survival in Kaplan-Meier analyses. This is in accordance
with other reports of CMV disease as a risk factor for
graft loss [4]. Schnitzler et al [6] found a detrimental ef-
fect of CMV disease on kidney graft survival, but only in
recipients with zero HLA-DR matches. In that study oral
ganciclovir prophylaxis was given to all patients (except
D− R−). On the other hand, no increased risk of graft
failure was found in the CMV risk group (D+ and/or
R+) in a small study of 84 renal graft recipients, where
those in the CMV risk group received ganciclovir intra-
venously prophylactically when treated with antilympho-
cyte globulins due to acute rejection [7]. Eriksson et al [8]
did not find any effect of CMV disease on graft survival
in another small study of 85 renal transplant recipients
of whom only two received ganciclovir prophylactically,
but in that study graft survival is not clearly defined. It is
obviously important to define graft loss censored or un-
censored to make comparisons meaningful. In our study
CMV seems to be associated with increased risk for death
rather than isolated effects on the graft.
In multiple analyses where recipient age is one of
the cofactors it seems most appropriate to use death-
censored graft loss, as was done in the present study. The
findings that donor age, serum creatinine and number of
HLA-AB plus DR mismatches came out as independent
risk factors for graft loss are in accordance with previous
reports [8, 22, 23]. Acute clinical rejection significantly in-
creased the risk of death-censored graft loss in univariate
analysis, in accordance with reports by Opelz [22].
Preemptive therapy has been appointed the treatment
of choice, at least in CMV seropositive recipients [24].
The same author advises prophylaxis in seronegative re-
cipients of seropositive donors. With preemptive therapy
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CMV disease is reduced [25, 26]. Moreover, a somewhat
small retrospective study indicated that preemptive ther-
apy against CMV may reduce uncensored graft loss [27].
Beneficial effects of preemptive therapy on graft and pa-
tient survival are also found in a larger, retrospective
study [28]. However, the two groups in that study are
not directly comparable. Also, the incidence of CMV in-
fection was low in that study.
It is possible that a preemptive therapy would have
modified the impact of CMV infection on long-term mor-
tality in our study. Evidently, preemptive therapy may
also reduce the AUC of CMV pp65 antigen. Obviously,
a potential beneficial effect of preemptive treatment on
graft and patient survival needs further study.
CMV is known to predispose to superinfection with a
variety of microbial agents [1]. The present study could
not reveal any effect of CMV infection or disease during
the first 100 days on later hospital-treated infections.
CONCLUSION
The present study confirms that both asymptomatic
CMV infection and overt CMV disease during the
first 100 days post-transplantation are independent
risk factors for overall recipient death beyond 100
days. Asymptomatic CMV infection or disease had no
detrimental effect on death censored graft loss, but sig-
nificantly reduced uncensored graft survival (Kaplan-
Meier). Whether CMV prophylaxis or preemptive CMV
therapy given routinely after kidney transplantation
would improve patient survival remains to be shown.
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